UCB/Amgen misses fracture punt after FDA moves goalposts
This article was originally published in Scrip
Executive Summary
UCB and Amgen's 50-50 collaboration on the novel sclerostin antibody romosozumab (CDP7851/AMG785) will not proceed into Phase III trials in fracture healing. The decision is based on two factors: firstly, the FDA has moved the goalposts for clinical studies in fracture healing, and secondly, in a Phase II trial investigating its use in accelerating tibial fracture healing, the drug was "not reaching its endpoint to our full satisfaction", according to a UCB spokesperson.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.